Concepedia

Daniel Sohn

DS

10

Publications

440

Citations

10

H-Index

1988

Active since

Affiliations

AstraZeneca (Sweden)(Current)

University of Pittsburgh

Centre for Addiction and Mental Health

University of Toronto

Daniel Sohn is an author at AstraZeneca (Sweden) specializing in pharmacology, biochemistry, and drug discovery.

ORCID

Top concepts

Publications per year

1988–2024

10

Publications

10

The Pharmacological Characterization of a Novel Selective 5-Hydroxytryptamine1A Receptor Antagonist, NAD-299

L. E. B. Johansson, Daniel Sohn, Seth-Olof Thorberg et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 130 citations · Full text

Substituted 7-Amino-5-thio-thiazolo[4,5-<i>d</i>]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX<sub>3</sub>CR1)

Sofia Karlström, Gunnar Nordvall, Daniel Sohn et al. · Journal of Medicinal Chemistry · 2013 · 68 citations · Full text

, , +18

Novel 2-Aminotetralin and 3-AminoChroman Derivatives as Selective Serotonin 5-HT<sub>7</sub> Receptor Agonists and Antagonists

Pär Holmberg, Daniel Sohn, Robert Leideborg et al. · Journal of Medicinal Chemistry · 2004 · 50 citations · Full text

Radiosynthesis, <i>In Vitro</i> and <i>In Vivo</i> Evaluation of [<sup>18</sup>F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies

Anton Lindberg, Ashley C. Knight, Daniel Sohn et al. · ACS Chemical Neuroscience · 2021 · 50 citations · Full text

Radiosynthesis and autoradiographic evaluation of [11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor

Johan Sandell, Christer Halldin, Håkan Hall et al. · Nuclear Medicine and Biology · 1999 · 34 citations

, , +7

Rows per page

1–5 of 10